Multiple Autoimmune Complications After a Single Dose of Pembrolizumab

Abstract

Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix

“…Most cases of hypothyroidism appear within the first one to three months of treatment and are managed with thyroid hormone replacement. Nevertheless, several case reports have described life-threatening toxicities following a single dose of anti-PD1 ( Ahdi et al, 2023 Mar 7 ). Thus, it is important to balance the expected benefits of a treatment against potential toxicities.…”